Skip to main content

Coronavirus: Vaccination

Question for Department for Business, Energy and Industrial Strategy

UIN 162590, tabled on 3 March 2021

To ask the Secretary of State for Business, Energy and Industrial Strategy, what proportion of the £6 billion of additional funding for vaccine development and procurement announced in Budget 2021 will be spent on (a) research and development, (b) manufacturing and (c) procurement; and if he will make a statement.

Answered on

12 March 2021

The UK was the first country in the world to procure, authorise, and start a vaccination programme using the Pfizer/BioNTech and Oxford/AstraZeneca vaccines. The Government has secured access to 457 million doses, across eight different vaccine developers. As of 11 March, over 22.8 million individuals have been vaccinated with a first dose in the UK.

At the Spending Review 2020, the Government announced it had made available more than £6 billion in total to develop, manufacture, and procure COVID-19 vaccines. Of that, we confirmed £733 million in 2021-22 to purchase successful vaccines and £128 million for research and development (R&D) and vaccines manufacturing. Further funding will be allocated from the COVID-19 reserve as needed.

For R&D, we have invested:

  • £33.6 million for the Human Challenge Programme.
  • £20 million to the University of Oxford to fund clinical trials for its COVID-19 vaccine.
  • Over £40 million to Imperial College London for the development of its vaccine.

At Budget 2021, the Government announced funding of:

  • £28 million to increase the UK’s capacity for vaccine testing, support for clinical trials, and to improve the UK’s ability to rapidly acquire samples of new variants of COVID-19.
  • £22 million for a world-leading study to test the effectiveness of combinations of different COVID-19 vaccines. This will also fund the world’s first study assessing the effectiveness of a third dose of vaccine to improve the response against current and future variants of COVID-19.
  • A further £5 million on top of a previous £9 million investment in clinical-scale mRNA manufacturing, to create a ‘library’ of vaccines that will work against COVID-19 variants for possible rapid response deployment.

For manufacturing, the Government has invested over £300 million to secure and scale-up the UK’s manufacturing capabilities to be able to respond to the pandemic. This includes:

a) Facilities that have come online:

  • £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres.
  • £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire.
  • £65.5 million for the early manufacture of the Oxford/AstraZeneca vaccine.
  • Funding for fill and finish capabilities through a contract with Wockhardt in Wrexham, North Wales which is currently providing fill and finish capabilities to the Oxford/AstraZeneca vaccine.

b) Facilities that will come online later this year, to help provide longer-term UK capacity:

  • £93 million to accelerate the completion and expanded role of the Vaccines Manufacturing Innovation Centre in Oxfordshire.
  • £127 million for the Cell and Gene Therapy Catapult in Braintree, Essex.

In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.

Answered by

Department for Business, Energy and Industrial Strategy